Christopher Rudd

Christopher E. Rudd is a distinguished immunologist and researcher with a focus on T-cell signaling and cancer immunotherapy. He currently holds several academic positions:

Academic Appointments

• Full-time Professor (accredited) at Université de Montréal in the Department of Microbiology, Infection and Immunology13
• Adjunct Professor in the Department of Medicine at McGill University24
• Full member of the McGill Centre for Translational Research in Cancer12

Research Focus

Dr. Rudd's research primarily concentrates on:

• Receptors and signaling pathways of T-cells in the immune system
• Control of T-cell reactivity and tumor rejection
• Identification of key mediators in T-cell function for cancer treatment

His lab has made significant contributions to the field, including:

• Discovery of CD4 and CD8-p56lck complexes and adaptor proteins
• Identification of pathways for CD28, CTLA-4, and ICOS co-receptor function
• Laying the foundation for chimeric antigen receptor (CAR) cancer therapy
• Identifying glycogen synthase kinase (GSK-3) as a central regulator of PD-1 expression on T cells1

Education and Career

Dr. Rudd received his BSc from McGill University in Canada and his Ph.D. and D.Sc. degrees from University College London in the UK.7 He has had a distinguished career in immunology research, holding various positions before his current roles at Université de Montréal and McGill University.

Honors and Affiliations

Christopher E. Rudd holds several prestigious titles:

• FRCPath (Fellow of the Royal College of Pathologists)
• FMedSci (Fellow of the Academy of Medical Sciences)
• FRSC (Fellow of the Royal Society of Canada)5

His LinkedIn profile, under the username chrudd, indicates that he is based in Montréal-Ouest and has over 500 connections in his professional network.6